YM BioSciences: Anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer

By Elaine Rigoli

Tampa, Fla., July 20 - YM BioSciences, Inc. said Thursday that India's Drug Controller General has granted marketing approval to nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head and neck cancer.

Biocon Biopharmaceuticals Ltd., a joint venture between Biocon and Cimab SA in Havana, Cuba, has rights to the drug from Cimab for the Indian subcontinent.

Nimotuzumab is also licensed to YM's majority owned subsidiary Cinym BioSciences, Inc. by Cimab for the major market areas including Europe, North America, Japan and the Pacific Rim countries, excluding China.

"While our license for nimotuzumab does not extend to India, this approval is an important validation of the safety and efficacy of the drug. In addition, a significant amount of additional clinical data in head and neck cancer will be now generated in India as nimotuzumab is commercialized," said David Allan, chairman and chief executive officer of YM BioSciences, in a statement.

YM BioSciences is a cancer product development company based in Mississauga, Ont.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.